Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioArctic AB (BIOA-B.ST)
SEK309.60
-4.40 (-1.40%)
SE STO Healthcare Biotechnology
Address
Warfvinges vag 35 112 51
Stockholm, AB, SE
Stockholm, AB, SE
CEO
Gunilla Osswald
Website
bioarctic.se
IPO
2017-10-12
ISIN SE0010323311
Also trades on
Other OTC · BRCTF (USD)
Stockholm Stock Exchange · BIOA-B.ST (SEK)
Description
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK309.60
-4.40 (-1.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
214.6K
Beta
-0.76
Float Shares
34.33M
Free Float %
38.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.54% | +5.20% | +5.53% | +8.47% | +10.18% | +7.98% | +86.34% | +5.73% | +301.92% | +1,057.24% | +1,057.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
309.60
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
38.36
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
-
Revenue growth Biotechnology: +1.6%+676.8% ★ Q1'26: -66.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+676.0% ★ Q1'26: -79.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+63.6% Q1'26: -37.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+68.4% ★ Q1'26: +51.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +417.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.2% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.05× ★ Q1'26: 0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 2 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
140.71M
est: 119.68M (+17.6%)
|
713.97M
est: 304.20M (+134.7%)
|
281.77M
est: 293.82M (-4.1%)
|
62.35M
est: 68.23M (-8.6%)
|
23.15M
est: 30.41M (-23.9%)
|
228.29M
est: 176.25M (+29.5%)
|
616.00M
est: 299.35M (+105.8%)
|
257.35M
est: 265.98M (-3.2%)
|
2.00B
est: 1.78B (+12.4%)
|
1.14B
1.01B – 1.29B
-35.9% YoY
|
1.72B
1.13B – 2.65B
+50.8% YoY
|
2.57B
2.50B – 2.64B
+49.5% YoY
|
4.48B
3.37B – 6.14B
+74.4% YoY
|
5.92B
4.45B – 8.11B
+32.1% YoY
|
| EBITDA |
26.02M
est: -51.34M (+150.7%)
|
487.89M
est: -130.48M (+473.9%)
|
123.37M
est: -126.03M (+197.9%)
|
-74.58M
est: -29.26M (-154.9%)
|
-126.42M
est: -13.05M (-869.1%)
|
4.03M
est: -75.60M (+105.3%)
|
295.29M
est: -27.17M (+1,186.7%)
|
-165.13M
est: -24.14M (-584.0%)
|
1.38B
est: -161.51M (+955.0%)
|
-103.50M
-117.13M – -91.32M
+35.9% YoY
|
-156.12M
-240.88M – -102.57M
-50.8% YoY
|
-233.34M
-239.61M – -227.06M
-49.5% YoY
|
-406.87M
-557.68M – -305.71M
-74.4% YoY
|
-537.40M
-736.58M – -403.78M
-32.1% YoY
|
| EBIT |
20.34M
est: -55.68M (+136.5%)
|
490.96M
est: -141.53M (+446.9%)
|
114.17M
est: -136.70M (+183.5%)
|
-85.71M
est: -31.74M (-170.0%)
|
-139.67M
est: -14.15M (-887.1%)
|
-10.61M
est: -82.00M (+87.1%)
|
276.81M
est: -38.43M (+820.3%)
|
-187.67M
est: -34.14M (-449.6%)
|
1.37B
est: -228.41M (+699.0%)
|
-146.37M
-165.66M – -129.15M
+35.9% YoY
|
-220.80M
-340.66M – -145.05M
-50.8% YoY
|
-329.99M
-338.86M – -321.12M
-49.5% YoY
|
-575.41M
-788.69M – -432.34M
-74.4% YoY
|
-760.01M
-1.04B – -571.04M
-32.1% YoY
|
| Net Income |
15.16M
est: -14.75M (+202.7%)
|
381.60M
est: 68.43M (+457.6%)
|
88.47M
est: 56.40M (+56.9%)
|
-68.52M
est: -69.75M (+1.8%)
|
-119.79M
est: -143.08M (+16.3%)
|
-11.18M
est: -63.28M (+82.3%)
|
229.25M
est: -88.28M (+359.7%)
|
-177.08M
est: -210.72M (+16.0%)
|
1.02B
est: 1.08B (-4.9%)
|
325.67M
117.14M – 444.60M
-69.7% YoY
|
841.73M
94.07M – 1.25B
+158.5% YoY
|
992.50M
316.22M – 1.51B
+17.9% YoY
|
2.25B
1.53B – 3.34B
+127.1% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
32.92M
est: 70.79M (-53.5%)
|
31.95M
est: 179.94M (-82.2%)
|
31.17M
est: 173.80M (-82.1%)
|
23.37M
est: 40.36M (-42.1%)
|
24.85M
est: 17.99M (+38.1%)
|
148.67M
est: 104.26M (+42.6%)
|
172.18M
est: 160.46M (+7.3%)
|
148.84M
est: 142.58M (+4.4%)
|
194.83M
est: 953.78M (-79.6%)
|
611.21M
539.29M – 691.73M
-35.9% YoY
|
921.98M
605.70M – 1.42B
+50.8% YoY
|
1.38B
1.34B – 1.42B
+49.5% YoY
|
2.40B
1.81B – 3.29B
+74.4% YoY
|
3.17B
2.38B – 4.35B
+32.1% YoY
|
| EPS |
0.22
est: -0.17 (+232.0%)
|
4.33
est: 0.77 (+460.2%)
|
1.00
est: 0.64 (+57.0%)
|
-0.78
est: -0.79 (+1.0%)
|
-1.36
est: -1.62 (+15.8%)
|
-0.13
est: -0.72 (+81.9%)
|
2.60
est: -1.00 (+359.6%)
|
-2.00
est: -2.20 (+9.1%)
|
11.55
est: 11.23 (+2.9%)
|
3.00
1.32 – 5.01
-73.3% YoY
|
7.15
1.06 – 14.10
+138.5% YoY
|
10.28
3.56 – 16.99
+43.8% YoY
|
25.40
17.19 – 37.64
+147.2% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-245.28M
OE per share TTM
-2.75
Owner's Yield
-0.82%
Maintenance CapEx ratio
41.28%
Maint CapEx / Avg PPE
10.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares OMX Stockholm Capped UCITS ETF OM3X.DE | 0.16% | 345.0K | 0.10% |
| 2 | iShares International Small-Cap Equity Factor ETF ISCF | 0.15% | 993.7K | 0.24% |
| 3 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.15% | 1.73M | 0.40% |
| 4 | iShares Ageing Population UCITS ETF AGED.L | 0.12% | 1.08M | 0.40% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.10% | 332.7K | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.10% | 332.7K | 0.23% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.09% | 160.9K | 0.41% |
| 8 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.09% | 3.11M | 0.30% |
| 9 | Avantis International Small Cap Equity ETF AVDS | 0.08% | 238.2K | 0.30% |
| 10 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.04% | 91.6K | 0.83% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
10.44M
Shares Outstanding
88.59M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gunilla Osswald | President & Chief Executive Officer | 12M | — |
| Lars Lannfelt | Co-Founder, Senior Vice President of Medical science & Director | 3M | — |
| Pär Gellerfors | Co-Founder, Senior Vice President of Business Strategy & Director | 336.0K | — |
| Christer Möller | Vice President of Pre-Clinical Development & Chief Scientific Officer | — | male |
| Emilie Ankarcrona Smith | General Counsel and Head of Legal & IP | — | female |
| Frida Lekander | Head of Marketing | — | female |
| Gabrielle Ahlberg Hillert | CMO and Head of Clinical & Regulatory Affairs | — | — |
| Harald Borgeke | Head of Public Affairs | — | male |
| Johanna Fälting | Chief R&D Officer and Head of Research & Development | — | female |
| Mats Ekelund | Head of Market Access | — | male |
| Mikael Moge | Vice President & Head of CMC | — | male |
| Oskar Bosson | Vice President and Head of IR & Communication | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOA-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
